Skip to main content
. 2019 Mar 17;12(5):764–774. doi: 10.1016/j.tranon.2019.02.014

Figure 2.

Figure 2

Baseline circulating tumor DNA (ctDNA) gene mutations in ER-positive/HER2-negative and ER-positive/HER2-positive MBC patients. Dark red represents the most common mutated genes, and dark blue represents the rarest mutations. If the mutated genes appeared at the same frequency, they are ranked in alphabetic order.

(A) Rank of the baseline ctDNA gene mutations in all ER-positive/HER2-negative patients (left) and in seven individual patients (ID=1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 22, 23, 33, 34, 35, 39,40, 41, 42, 44).

(B) Rank of the baseline ctDNA gene mutations in all ER-positive/HER2-positive patients (left) and in 12 individual patients (ID=20, 25, 26, 27, 28, 29, 30, 31, 36, 37, 38, 43).